{
}
UBS has lowered its price target for Cytokinetics (CYTK) from $47 to $41, maintaining a Neutral stance due to ongoing challenges. Despite this, analysts project an average target price of $77.30, indicating a potential upside of 111.51% from the current price of $36.55. The company reported significant revenue growth in Q4 2024, driven by partnerships, and holds $1.2 billion in cash, positioning it well for future initiatives.
UBS has lowered its price target for Regeneron (REGN) from $768 to $633, maintaining a Neutral rating amid uncertainties regarding Eyelea's transition to Eyelea HD. Analysts project an average target price of $840.59, indicating a potential upside of 43.99% from the current price of $583.79. Regeneron reported Q1 2025 revenue of $3 billion, with Dupixent sales rising 20% year-over-year, while EYLEA US net sales fell 39%. The company continues to invest heavily in R&D, with over $7 billion earmarked for US expansions.
UBS has lowered its price target for Regeneron Pharmaceuticals from $768 to $633 while maintaining a neutral rating. The company focuses on developing and selling drugs for ophthalmologic and inflammatory diseases and cancers, with product sales accounting for 53.7% of its revenue. Regeneron has a robust pipeline, with around 40 products in clinical development as of the end of 2024.
UBS has upgraded SANOFI to a 'Buy' rating, indicating a positive outlook for the stock. However, the information provided is for informational purposes only and does not constitute a recommendation to buy or sell. Investors are reminded of the risks involved in purchasing securities, which may lead to total capital loss.
UBS has upgraded SANOFI to a 'Buy' rating, indicating a positive outlook for the stock. However, the information provided is for informational purposes only and does not constitute a recommendation to buy or sell. Investors are reminded of the risks involved in purchasing securities, which may lead to total capital loss.
UBS maintains a "Buy" rating on Sanofi but has lowered its target price. BOURSORAMA, acting solely as a distribution channel, emphasizes that it has not influenced the analysis and holds no conflicts of interest regarding the investment recommendations provided. The content is for informational purposes only.
Tidjane Thiam, the former CEO of Credit Suisse, has been barred from running in the upcoming Ivorian presidential election due to a court ruling on his nationality. He plans to appeal the decision to the Court of Justice of the Economic Community of West African States (ECOWAS), stating, "It’s me or no one," as his party will not nominate another candidate. This ruling follows the removal of other political opponents from the electoral roll, including former president Laurent Gbagbo.
Analysts have updated their recommendations and price targets for several companies, reflecting varied market sentiments. Notable changes include Bakkafrost upgraded to Buy by DNB Markets, while Eni was downgraded to neutral by Redburn Atlantic. Other adjustments include price target reductions for TotalEnergies, UBS Group, and Bolloré, alongside upgrades for Inditex and Mowi.
In Paris, the health sector shows resilience as Eurofins Scientific and Sanofi rise amid a downbeat CAC 40, unaffected by upcoming U.S. tariffs set for April 2025. However, UBS warns that the sector may still face challenges, including potential additional tariffs from Trump targeting pharmaceuticals. Sartorius Stedim Biotech sees a decline, reflecting concerns over U.S. sales exposure and tariff implications.
Barclays has maintained an 'Overweight' rating for Sanofi, noting the company's positive trajectory into FY25. As the largest European pharmaceutical group, Sanofi's net sales are primarily driven by pharmaceutical products (79.8%), with a focus on specialty and general medicine, alongside human vaccines (20.2%). The company operates 52 production sites globally, with significant sales in the U.S. (48.7%) and Europe (22%).
Sanofi
Companies
| Symbol | SNY |
| Name | Sanofi |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Pharmaceuticals |
| Market | NASDAQ Global Select |
| Country | France |
| State | |
| City | Paris |
| Zipcode | 75008 |
| Website | http://www.sanofi.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs lowers price target for cytokinetics amid ongoing challenges
16:19 02.05.2025
ubs lowers price target for regeneron amid eyelea uncertainties
16:01 30.04.2025
ubs lowers price target for regeneron pharmaceuticals maintains neutral rating
15:40 30.04.2025
ubs upgrades sanofi to buy amid investment considerations and risks
13:53 28.04.2025
ubs upgrades sanofi to buy amid investment considerations and risks
13:16 25.04.2025
Sanofi receives buy rating from UBS with revised target price
11:30 25.04.2025
court bars former credit suisse ceo from presidential election in ivory coast
Novartis AG
Hoffmann-La Roche AG
Sanofi
CHE
CIV
FRA
RUS
USA
Tidjane Thiam
Guy Parmelin
Laurent Gbagbo
Karin Keller-Sutter
Klaus Schwab
Show more
16:00 23.04.2025
analysts update recommendations and price targets for major european companies
Swiss Franc
Euro
United States Dollar
Norwegian Krone
Danish Krone
Bakkafrost PF
Eni S.p.A.
Lectra
Enersense International Oyj
Euronext N.V.
Mowi ASA
Interparfums, Inc.
INDITEX
Michelin
Adecco Group AG
ABB Ltd
Tomra Systems ASA
BNP Paribas SA
Sartorius Stedim Biotech S.A.
Orsted A/S
Holmen AB
Bolloré SE
Pluxee N.V.
Eiffage SA
UBS Group AG
TotalEnergies SE
Gestamp Automocion SA
Vivendi SE
Hellenic Telecommunications Organization S.A.
Robertet SA
OVH Groupe
Sanofi
Show more
08:31 23.04.2025
health sector shows resilience amid potential us tariffs on pharmaceuticals
Euro
MedinCell S.A.
Sartorius Stedim Biotech S.A.
Sanofi
Eurofins Scientific S.E. A
Ipsen S.A.
FRA
USA
Charles Weston
Donald Trump
Show more
11:33 03.04.2025
barclays maintains overweight rating on sanofi as it progresses into fy25
16:41 01.04.2025
Trending
Subcategory
Countries:
Companies:
Currencies:
People: